Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (
Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointin
Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC),
The FDA has kicked off a priority review of Genfit and Ipsen’s elafibranor as a treatment for rare cholestatic liver disease primary biliary cholangitis (PBC), setting a d
Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with the drug in other indications – and
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.